U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06887673) titled 'Lipid Mediators & Cancer: Montelukast, SPM, and Almonds' on Feb. 25.
Brief Summary: The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endometrial cancer, and ovarian cancer). The focus will be on assessing changes in lipid mediator concentrations, TAM reprogramming, and immune cell function in treated versus untreated patients. It is hypothesized that montelukast will reduce the pro-inflammato...